Nepsone is a preclinical-stage pharmaceutical company developing drugs to treat dermatological conditions that arise due to an imbalance in the autonomic nervous system.

Currently, these conditions are believed to originate in the immune system. Nepsone’s foundational neuroimmunology theory on the origin of psoriasis teaches us that an imbalance in neuropeptide activity in the body leads to these conditions.

Our drugs are designed to utilize the body’s natural mechanisms to bring back balance and alleviate the disease.


Nepsone’s drug discovery platform can potentially address over 10 indications in total.

Psoriasis (Lead Indication)

Phase: Preclinical

Modalities: Topical and Systemic

Alopecia Areata

Phase: Research and Discovery

Modality: Topical

There are currently no approved drugs for the treatment of alopecia areata.

Eczema (Atopic Dermatitis)

Phase: Research and Discovery

Modality: Topical


Grant from Tækniþróunarsjóður


Nepsone ehf has been awarded a grant from Tækniþróunarsjóður (Technology Development Fund) of Rannís (The Icelandic Centre for Research). The award for 50 mISK will support the preclinical development of a topical psoriasis treatment based on Nepsone’s novel neuro-immunological theory on the origins of psoriasis. Psoriasis patients have not received a novel mechanism of action in the form of a topical treatment in over 20 years.

Nepsone at Biotech Showcase


Nepsone ehf has been selected to present at the Biotech Showcase during the JP Morgan Meeting in San Francisco, CA. The 15-minute presentation will take place on Wednesday, January 9th, 2019, at 11:15 AM at the Hilton San Francisco Union Square (Franciscan B).

The People of Nepsone

Birkir Sveinsson

CEO / Member of the board

Sirus B. Palsson


Bjarki Gudlaugsson

CIO / Member of the board

David Olafsson


Tomas Thorvaldsson

Chairman of the board

Ragnar Bjarnason

Member of the board

Hakon Hrafn Sigurdsson

Member of the board

Contact Us

Nepsone ehf.
Hverfisgata 105
101 Reykjavik

+354 555 1634